Ads
related to: alternative glaucoma treatment options and outcomes research journal
Search results
Results From The WOW.Com Content Network
Glaucoma is a group of diseases affecting the optic nerve that results in vision loss and is frequently characterized by raised intraocular pressure (IOP). There are many glaucoma surgeries, and variations or combinations of those surgeries, that facilitate the escape of excess aqueous humor from the eye to lower intraocular pressure, and a few that lower IOP by decreasing the production of ...
Physostigmine, an acetylcholinesterase inhibitor, can be used to treat glaucoma and delayed gastric emptying.Because it enhances the transmission of acetylcholine signals in the brain and can cross the blood–brain barrier, physostigmine salicylate is used to treat anticholinergic poisoning (that is, poisoning by substances that interfere with the transmission of acetylcholine signaling, such ...
Treatment typically includes prescription of eye drops, medication, laser treatment or surgery. [1] [9] The goal of these treatments is to decrease eye pressure. [2] Glaucoma is a leading cause of blindness in African Americans, Hispanic Americans, [10] [11] and Asians. [12]
Steroidal treatment is also used in management of aphakic, pseudophakic, and post-traumatic glaucoma. Inflammatory glaucoma may further be treated using cycloplegics , a class of drugs that treats pain, ciliary spasm, uveoscleral tract blockage and disrupted blood-aqueous barrier linked with this form of glaucoma. [ 2 ]
Recently, central serous chorioretinopathy has been understood to be part of the pachychoroid spectrum. [5] [6] In pachychoroid spectrum disorders, of which CSR represents stage II, the choroid, the highly vascularized layer below the retina, is thickened and congested with increased blood vessel diameter, especially in the deep choroid (the so-called Haller's layer).
Expert Review of Pharmacoeconomics & Outcomes Research is a bimonthly peer-reviewed medical journal covering all aspects of pharmacoeconomics. It was established in 2001 and is published by Informa. The editor-in-chief is A. Bottomley (European Organisation for Research and Treatment of Cancer).